Compugen Ltd

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Market Capitalization 162.05 M
Employee 74
Founded 1993
CEO Anat Cohen-Dayag
Website www.cgen.com
Headquarter Israel
FIGI UNKNOWN
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

162.05 M Market capitalization

Price to earnings ratio

-9.56

Price to sales ratio

4.92

Dividends per share

—

Dividend yield %

—

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.